investigation for the treatment of sepsis associated ARDS, the leading cause of death associated with COVID-19
A cannabinoid medicines development company undertaking extensive clinical programs, guided by our medical advisory board.
Therapeutic products under development, and patent protection strategies, have no existing pharmacotherapy treatments available to patients, representing global market opportunities.
Clinical programs are informed by existing bodies of research, underpinning our procession to in-human trials.
Impression also has its Australian licenses in place to import, export and distribute medicinal cannabis products.
We’ve launched our own line of pharmaceutical grade cannabinoid products under the brand name Incannex Pharmaceuticals.
Incannex formulations have been designed to match those product-types that are most in-demand.
Board and Management
Joel has over 13 years’ experience, with blue chip firms including Mars Foods, Tabcorp and Philip Morris International. Prior to Joel’s appointment to CEO, he was the General Manager of Impression healthcare for a period of 3 years. During this time, he was instrumental in the marketing and procurement of multiple revenue-generating opportunities and collaborations, including with Pacific Smiles (ASX:PSQ), the NRL and AFL and implementation of Gameday’s ambassadorial program.
Dr Agarwal is a qualified anaesthetist and the former Medical Director of Cann Group Limited (CAN:ASX), during the early stages of its strategy development. He is considered one of the most influential people in the medicinal cannabis sector, as evidenced by being a recent keynote speaker at the World Cannabis Congress 2019 (held in New Brunswick, Canada) and being the advisor to numerous government and non-government bodies on medicinal cannabis.
Troy has 25 years of experience in Stockbroking, Corporate Finance and Capital Markets. Originally from Perth, he began with Hartley Poynton in 1994 before moving to Patersons Securities in 2000 where he became an Associate Director of Private Clients. During this time, he was responsible for managing both retail and institutional accounts. Mr Valentine has significant corporate and capital raising experience, specifically with small to mid-cap size companies and is currently a director of the boutique corporate advisory group Alignment Capital Pty Ltd based in Melbourne.
Mr Widdows is a highly-experienced Fast-Moving Consumer Goods (FMCG) expert with over 17 years of experience in senior global executive positions at H.J. Heinz Corporation. Mr Widdows was the CEO and Managing Director of H.J. Heinz Company Australia between February 2003 and October 2008. During his tenure, Heinz Australia sales trebled, and the net profit grew by 5.5x. Following this, he moved into a regional CEO role covering Australasia and a large part of Asia with responsibility for 18,500 employees and revenues of US$1.8B. Mr Widdows, based in Melbourne, has a strong commercial acumen, deep experience in all business functions and is a Chartered Accountant.
17 years’ experience at Contango Asset Management Ltd in roles including executive director, COO and Company Secretary. Former COO and Executive Director of HSBC Asset Management. Former CFO and Company Secretary of Global Health Ltd.